Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152796 | 1.00 | LMNA (0.51) | LMNADRD2DRD3MEN1KMT2A | |
| SCHEMBL1152486 | 0.94 | LMNA (0.56) | LMNADRD2DRD3MEN1KMT2A | |
| SCHEMBL1152484 | 0.94 | LMNA (0.56) | LMNADRD2DRD3MEN1KMT2A | |
| Fumaric Acid SCHEMBL9809236 | 0.87 | LMNA (0.51) | LMNADRD2DRD3MEN1KMT2A | |
| Fumaric Acid SCHEMBL9809238 | 0.87 | LMNA (0.51) | LMNADRD2DRD3MEN1KMT2A | |
| Fumaric Acid SCHEMBL9809232 | 0.87 | LMNA (0.51) | LMNADRD2DRD3MEN1KMT2A | |
| SCHEMBL1152774 | 0.86 | LMNA (0.61) | LMNADRD2DRD3MEN1KMT2A | |
| SCHEMBL1152771 | 0.86 | LMNA (0.61) | LMNADRD2DRD3MEN1KMT2A | |
| SCHEMBL1151665 | 0.83 | LMNA (0.57) | LMNADRD2DRD3MEN1KMT2A | |
| SCHEMBL1151668 | 0.83 | LMNA (0.57) | LMNADRD2DRD3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| EP-0232205-A3 | DIENE DERIVATIVES AND VASODILATORS CONTAINING THE SAME | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1989-01-25 | — | — | EP | disclosed |
| US-4792553-A | TREATMENT OF CARDIOVASCULAR AND CEREBROVASCULAR DISORDERS | TERUMO KABUSHIKI KAISHA (JP) | 1988-12-20 | — | — | US | disclosed |
| US-4792553-A | TREATMENT OF CARDIOVASCULAR AND CEREBROVASCULAR DISORDERS | TERUMO KABUSHIKI KAISHA (JP) | 1988-12-20 | — | — | US | disclosed |
| EP-0232205-A2 | Diene derivatives and vasodilators containing the same | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1987-08-12 | — | — | EP | disclosed |
| EP-0232205-A2 | Diene derivatives and vasodilators containing the same | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | LMNA 156/4885DRD2 4871/4885DRD3 4854/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | LMNA 156/4885DRD2 4871/4885DRD3 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.